$31.730
+2.561 (+8.07%)收盘时
QNCX 同业对比
In the context of the broader market, QNCX competes directly with industry leaders such as RNAZ and CVM. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, QNCX's gross margin of N/A stands against RNAZ's N/A and CVM's N/A. Such benchmarking helps identify whether IRulya Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Quince Therapeutics Inc 财务表现
Quince Therapeutics has shown significant volatility in its financial performance, with a net income loss of $75,488,000 in Q2 2026. However, it posted a positive net income of $35,912,000 in Q1 2026, indicating potential recovery.
Financials
FY2026Q2
0.00
Total Revenue
FY2026Q2
YoY:
+114.52%
-21.23M
Operating Profit
FY2026Q2
YoY:
+370.36%
-75.49M
Net Income after Tax
FY2026Q2
YoY:
-82.09%
-12.31
EPS - Diluted
FY2026Q2
YoY:
+63.65%
-18.89M
Free Cash Flow
相关文章
- Equal-Weight vs Cap-Weighted S&P 500: RSP vs SPY After October's Rotation and Nvidia's CEO ShockEqual weight vs cap weighted S&P 500: how RSP and SPY differ, why October 2026's rotation was the widest since 2009, and how to blend both after Nvidia's shock.
- Money Market Funds vs High-Yield Savings vs T-Bills: Where to Park Cash as the Fed HikesMoney market funds, high-yield savings or T-bills? Compare November 2026 yields, taxes, FDIC rules and liquidity as the Fed hikes, and build a smart cash plan.
- Homebuilder Stocks With Mortgage Rates Above 7%: An Investor's Guide for Late 2026Homebuilder stocks face 7% mortgage rates and a 16-year low in home sales. See what D.R. Horton, Lennar and Pulte earnings show and how to invest in 2026.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。